—Using multimodal imaging, this 10-year prospective cohort study identified markers that could help stratify patients at high risk of progressing to advanced AMD, which may help inform clinical ...
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or ...
DEFENDOR SPECIAL: Effect of primary prophylaxis with empegfilgrastim on pCR rate after neoadjuvant TCHP in early HER2+ breast cancer patients—Matching-adjusted indirect comparison (MAIC). This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results